Ultragenyx Pharmaceutical (RARE) Income from Continuing Operations (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has 14 years of Income from Continuing Operations data on file, last reported at 185000000.0 in Q1 2026.

• On a quarterly basis, Income from Continuing Operations fell 22.52% year-over-year to 185000000.0 in Q1 2026; TTM through Mar 2026 was 602920000.0, a 10.56% decrease from a year earlier, with the FY2025 full-year figure at 569000000.0, down 0.71% from the prior year.
• Income from Continuing Operations for Q1 2026 stood at 185000000.0, down from 122556000.0 in the prior quarter.
• Over the last five years, Income from Continuing Operations for RARE reached as high as 114951000.0 in Q2 2025 and fell as low as 245106000.0 in Q3 2022.
• Historically, Income from Continuing Operations has averaged 154998882.35 across 5 years, with a median of 153473000.0 in 2022.
• Across the five-year window, Income from Continuing Operations plunged 235.77% in 2022 and surged 34.87% in 2023, its largest moves.
• Year by year, Income from Continuing Operations stood at 153473000.0 in 2022, then grew by 19.5% to 123551000.0 in 2023, then dropped by 4.57% to 129202000.0 in 2024, then advanced by 5.14% to 122556000.0 in 2025, then slumped by 50.95% to 185000000.0 in 2026.
• Per Business Quant data, the three most recent Income from Continuing Operations figures were 185000000.0 in Q1 2026, 122556000.0 in Q4 2025, and 180413000.0 in Q3 2025.